The enrichment of proliferative and metabolic pathways, coupled with the suppression of genes linked to angiogenesis and hypoxia, suggests that SIGLEC9 may support cancer cell adaptation to challenging tumor conditions without engaging processes like angiogenesis. This evidence concerns the gene SIGLEC9 and cancer.